WADA S2
This substance falls under WADA S2 (Peptide Hormones, Growth Factors, Related Substances and Mimetics). If you are subject to anti-doping rules, this category of substances is prohibited at all times.
GH Axis
This substance modulates the growth hormone axis. GH-axis stimulation carries risks including glucose intolerance, fluid retention, and theoretical concerns about sustained IGF-1 elevation.
Evidence visual
Sermorelin evidence and risk matrix
intermediate researcher fit
Evidence
Tier B
Risk
medium
Regulatory
not approved
WADA
S2
FDA
unknown
Route
subcutaneous
Higher-confidence evidence profile, but regulatory and sourcing checks still matter.
Overview
Sermorelin stimulates pituitary GH secretion via GHRH receptor signaling, intended to preserve pulsatile GH dynamics compared to exogenous GH. Pediatric therapy literature includes daily subcutaneous dosing around 30 µg/kg in GH-deficient children. GH-axis stimulation risks include glucose intolerance and theoretical neoplasia concerns when IGF-1 is elevated.
Decision path
Where Sermorelin fits in the research path.
Use the evidence and risk profile first, then compare vendors and run the quiz before turning this compound into a protocol decision.
01
Read evidence
02
Check risk
03
Compare options
04
Build plan
Peptide research path
Decide whether Sermorelin belongs in your plan.
Use the quiz before choosing a compound, vendor, or PDF. It routes by goal, experience, budget, safety flags, and monitoring comfort.
Research Details
Stimulates pituitary GH secretion via GHRH receptor signaling; preserves pulsatile GH dynamics.
subcutaneous
Pediatric: daily subcutaneous ~30 µg/kg in GH-deficient children.
GH axis stimulation; growth/body composition changes over months.
GH secretion changes occur acutely; body composition endpoints are months-horizon.
Active malignancy (by analogy to tesamorelin class warnings).
Glucose intolerance risk; theoretical neoplasia concerns with sustained IGF-1 elevation.
Unknown interaction profile outside supervised settings.
Cost at a glance
Typical cycle cost
$480.00
Estimated monthly
$160.00
Protocol style
8-12 week phase
Phase-based
Estimate confidence
High confidence
Assumes roughly 24 mg–48 mg per cycle, using 1 tracked affiliated listing.
Assumes a classic multi-week GH-secretagogue protocol with follow-up labs.
Known Interactions
GHRH analog + GHS-R agonist: additive GH release plausible.
GHRH analog + GHS-R agonist: additive GH release plausible.
GHRH analog + GHS-R agonist: additive GH release plausible.
MK-677 and sermorelin both push GH-axis signaling through different levers; treat as additive endocrine load.
Information provided for educational and research reference only. Not medical advice. Not for diagnosing, treating, curing, or preventing disease. Products referenced are labeled Research Use Only (RUO) by vendors; not for human or veterinary use.
Sources and review notes
- Certain Bulk Drug Substances for Use in Compounding that May Present Significant Safety Risks - U.S. Food and Drug Administration - accessed 2026-05-15
Used for FDA compounding-risk context and peptide safety flags.
- The Prohibited List - World Anti-Doping Agency - accessed 2026-05-15
Used for athlete-facing WADA risk and peptide-class restrictions.
- Peptide therapeutics: current status and future directions - PubMed / Nature Reviews Drug Discovery - accessed 2026-05-15
Used for broad peptide-therapeutics background and evidence framing.
Personalized peptide routing
Find the right path for Sermorelin.
Take the quiz before choosing a compound, vendor, or PDF. We match your goal, experience, budget, and monitoring comfort to the next best step in the funnel.
- Goal-matched compound and protocol recommendations.
- Budget and sourcing filters before you leave the site.
- PDF unlocks shown after your personalized result.